Navigation Links
CVS Caremark Reports Second Quarter Results
Date:8/4/2011

WOONSOCKET, R.I., Aug. 4, 2011 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS), today announced revenues, operating profit, and net income for the three months ended June 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

Second Quarter Year-Over-Year Highlights:

  • Net revenues increased 10.9% to a record $26.6 billion
  • Pharmacy Services segment revenues increased 23.2%
  • Retail Pharmacy segment revenues increased 3.6%, with same stores sales up 2.0%
  • Adjusted EPS from continuing operations of $0.65
  • GAAP diluted EPS from continuing operations of $0.60

  • Year-to-Date Highlights:

  • Generated free cash flow of $2.4 billion
  • Generated cash flow from operations of $3.1 billion

  • Guidance:

  • Company narrows 2011 EPS guidance range
  • Full-year adjusted EPS from continuing operations revised to $2.75 - $2.81
  • Full-year GAAP diluted EPS from continuing operations revised to $2.55 - $2.61

  • RevenuesNet revenues for the three months ended June 30, 2011 increased $2.6 billion to $26.6 billion, up from $24.0 billion during the three months ended June 30, 2010.

    Revenues in the Pharmacy Services segment increased 23.2% to $14.6 billion in the three months ended June 30, 2011. This increase was primarily associated with the addition of a previously-announced, long-term contract with Aetna, Inc., as well as new activity resulting from our acquisition of the Medicare prescription drug business of Universal American Corp. ("UAM Medicare Part D Business").  Pharmacy network claims processed during the three months ended June 30, 2011 increased 35.6% to 174.0 million, compared to 128.3 million in the prior year period. The increase in pharmacy network claims was primarily due to the Aetna contract, the Company's recent acquisition of the UAM Medicare Part D Business, as well as an increase in covered lives in our existing Medicare Part D Business. Mail Choice claims processed during the three months ended June 30, 2011 increased approximately 11.3% to 17.8 million compared to 16.0 million in the prior year period. The increase in the Mail Choice claim volume was also driven by the Aetna contract.

    Revenues in the Retail Pharmacy segment increased 3.6% to $14.8 billion in the three months ended June 30, 2011. Same store sales increased 2.0% over the prior year period. Pharmacy same store sales rose 2.6%, and include a positive impact from Maintenance Choice™ of approximately 160 basis points on a net basis (i.e., a positive impact of approximately 190 basis points on a gross basis, net of approximately 30 basis points from the conversion of 30-day prescriptions at retail to 90-day prescriptions under the Maintenance Choice program).  Pharmacy same store sales were negatively impacted by approximately 170 basis points due to recent generic introductions. Front store same store sales increased 0.8% in the three months ended June 30, 2011. As expected, front store sales were positively impacted by approximately 45 basis points due to the shift of sales related to the Easter holiday into the second quarter.

    Income from Continuing Operations Attributable to CVS CaremarkIncome from continuing operations attributable to CVS Caremark for the three months ended June 30, 2011, decreased $5 million to $817 million, compared with $822 million during the three months ended June 30, 2010. The decline in income from continuing operations was driven by lower gross profit in the Pharmacy Services segment.  This was primarily the result of pricing compression relating to contract renewals and, in particular, the renewal of a large government contract that took effect during the third quarter of 2010.  As expected, this was partially offset by an improvement in the Company's effective income tax rate during the quarter to 39.2% compared to 39.8% in the prior year period.  Adjusted earnings per share from continuing operations attributable to CVS Caremark ("Adjusted EPS") for both the three months ended June 30, 2011 and 2010 was $0.65. Adjusted EPS excludes $114 million and $106 million of intangible asset amortization related to acquisition activity in the three months ended June 30, 2011 and 2010, respectively.  GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for both the three months ended June 30, 2011 and 2010 was $0.60.

    Larry Merlo, President and Chief Executive Officer, stated, "I'm very pleased with our second quarter results, which were at the high end of our guidance. While our Pharmacy Services business performed as expected, the Retail business exceeded our goals due to solid expense control and higher than expected generic utilization.  At the same time, we generated more than $800 million in free cash in the quarter, bringing our year-to-date free cash flow to $2.4 billion."

    Mr. Merlo continued: "We've made terrific progress on our five-point plan for PBM profit improvement. Our PBM has had an outstanding selling season to date, with excellent retention of existing business as well as a number of significant new business wins.  We've seen increased adoption of our differentiated product offerings, such as Maintenance Choice and Pharmacy Advisor, clearly demonstrating that our model is resonating with payors.
    Furthermore, we have made good progress on the integration of the Universal American Medicare Part D Business, the implementation of the Aetna contract, and the streamlining initiatives to generate significant efficiencies within our PBM. Combined, these efforts should generate healthy performance in our PBM in the years ahead."

    Acquisition of Universal American Medicare Part D BusinessOn April 29, 2011, the Company acquired the UAM Medicare Part D Business for approximately $1.3 billion. The UAM Medicare Part D Business offers prescription drug plan benefits to Medicare beneficiaries throughout the United States through its Community CCRx(SM) prescription drug plan.  With the inclusion of this acquisition, the Company now provides Medicare Part D benefits to over 3 million beneficiaries.

    Real Estate ProgramDuring the three months ended June 30, 2011, the Company opened 41 new retail drugstores and closed two retail specialty pharmacy stores, five specialty mail order pharmacies, one retail apothecary pharmacy store and one retail drugstore. In addition, the Company relocated 18 retail drugstores. As of June 30, 2011, the Company operated 7,346 locations, included in which were 7,266 retail drugstores, 31 specialty pharmacy stores, 32 apothecary pharmacy stores, 13 specialty mail order pharmacies and four mail order pharmacies in 44 states, the District of Columbia and Puerto Rico.

    GuidanceTaking into account the solid results reported year to date, continued confidence in the remainder of the year, and incremental start-up costs for the significant 2012 new business, the Company narrowed its earnings per share guidance range for the full year 2011.  The Company now expects adjusted EPS from continuing operations to be in the range of $2.75 to $2.81 and GAAP earnings per share from continuing operations to be in the range of $2.55 to $2.61, compared to its previous guidance range of $2.72 to $2.82, and $2.52 to $2.62, respectively.

    Teleconference and WebcastThe Company will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss its quarterly results. An audio webcast of the conference call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com/investors. This webcast will be archived and available on the website for a one-year period following the conference call.

    About the CompanyCVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,200 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company's website at http://info.cvscaremark.com .

    Forward-Looking StatementsThis press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.

    – Tables Follow –CVS CAREMARK CORPORATIONCondensed Consolidated Statements of Income(Unaudited)Three Months EndedSix Months EndedJune 30, June 30,In millions, except per share amounts

    2011201020112010Net revenues

    $
    26,629$
    24,007$
    52,509$
    47,767Cost of revenues

    21,53418,98742,66338,001Gross profit

    5,0955,0209,8469,766Operating expenses

    3,6053,5197,0456,855Operating profit

    1,4901,5012,8012,911Interest expense, net

    148135282263Income before income tax provision

    1,3421,3662,5192,648Income tax provision

    5265449901,054Income from continuing operations

    8168221,5291,594Loss from discontinued operations, net of tax

    (1)(1)(2)(3)Net income

    8158211,5271,591Net loss attributable to noncontrolling interest

    1—21Net income attributable to CVS Caremark

    $
    816$
    821$
    ,529$
    ,592Basic earnings per common share:

      Income from continuing operations attributable to CVS Caremark

    $
    .60 $
    .61 $
    .13 $
    .16Loss from discontinued operations attributable to CVS Caremark8212;8212;8212;8212;Net income attributable to CVS Caremark

    $
    .60$
    .61$
    .13$
    .16Weighted average basic common shares outstanding

    1,3551,3591,3591,372Diluted earnings per common share: Income from continuing operations attributable to CVS Caremark

    $
    .60 $
    .60 $
    .12$
    .15Loss from discontinued operations attributable to CVS Caremark8212;8212;8212;8212;Net income attributable to CVS Caremark

    $
    .60$
    .60$
    .12$
    .15Weighted average diluted common shares outstanding

    1,3641,3691,3681,381Dividends declared per common share

    $
    .1250$  0.0875$  0.2500$  0.1750CVS CAREMARK CORPORATIONCondensed Consolidated Balance Sheets(Unaudited)In millions, except per share amounts

    June 30,

    2011December 31,

    2010Assets:Cash and cash equivalents

    $  2,228$  1,427Short-term investments

    54Accounts receivable, net

    5,8924,925Inventories

    10,11110,695Deferred income taxes

    502511Other current assets

    327144Total current assets

    19,06517,706Property and equipment, net

    8,4838,322Goodwill

    26,69725,669Intangible assets, net

    10,0229,784Other assets

    1,220688Total assets

    $  65,487$  62,169Liabilities:Accounts payable

    $  4,446$  4,026Claims and discounts payable

    3,0612,569Accrued expenses

    3,3293,070Short-term debt

    —300Current portion of long-term debt

    9161,105Total current liabilities

    11,75211,070Long-term debt

    10,1688,652Deferred income taxes

    3,9483,655Other long-term liabilities

    1,3431,058Commitments and contingencies Redeemable noncontrolling interest

    3234Shareholders' equity:Preferred stock, par value $0.01: 0.1 shares authorized; none issued or
    outstanding

    ——Common stock, par value $0.01: 3,200 shares authorized; 1,633 shares issued and 1,346 shares outstanding at June 30, 2011 and 1,624 shares issued and 1,363 shares outstanding at December 31, 2010

    1616Treasury stock, at cost: 285 shares at June 30, 2011 and 259 shares at December 31, 2010

    (9,956)(9,030)Shares held in trust: 2 shares at June 30, 2011 and December 31, 2010

    (56)(56)Capital surplus

    27,90227,610Retained earnings

    20,49119,303Accumulated other comprehensive loss

    (153)(143)Total shareholders' equity

    38,24437,700Total liabilities and shareholders' equity

    $  65,487$  62,169CVS CAREMARK CORPORATIONCondensed Consolidated Statements of Cash Flows(Unaudited)Six Months EndedJune 30,In millions

    20112010Cash flows from operating activities:  Cash receipts from revenues

    $
    47,950$
    45,745  Cash paid for inventory and prescriptions dispensed by retail network pharmacies

    (37,307)(35,386)  Cash paid to other suppliers and employees

    (6,149)(7,129)  Interest received

    22  Interest paid

    (298)(284)  Income taxes paid

    (1,125)(1,236)Net cash provided by operating activities

    3,0731,712Cash flows from investing activities:  Purchases of property and equipment

    (710)(866)  Proceeds from sale-leaseback transactions

    11—  Proceeds from sale of property and equipment

    —10  Acquisitions (net of cash acquired) and other investments

    (1,366)(25)  Purchase of short-term investments

    (2)—  Maturity of short-term investments

    11Net cash used in investing activities

    (2,066)(880)Cash flows from financing activities:  Increase (decrease) in short-term debt

    (300)1,537  Proceeds from issuance of long-term debt

    1,463991  Repayments of long-term debt

    (302)(1,751)  Dividends paid

    (341)(241)  Derivative settlements

    (19)(5)  Proceeds from exercise of stock options

    264145  Excess tax benefits from stock-based compensation

    —13  Repurchase of common stock

    (971)(1,500)Net cash used in financing activities

    (206)(811)Net increase in cash and cash equivalents

    80121Cash and cash equivalents at beginning of period

    1,4271,086Cash and cash equivalents at end of period

    $  2,228$
    ,107Reconciliation of net income to net cash provided by operating activities:  Net income

    $  1,527$  1,591  Adjustments required to reconcile net income to net cash provided by operating activities:Depreciation and amortization

    765726Stock-based compensation

    6575Deferred income taxes and other non-cash items

    129(20)Change in operating assets and liabilities, net of effects of acquisitions:Accounts receivable, net

    (472)356Inventories

    584(46)Other current assets

    (164)(31)Other assets

    (62)(4)Accounts payable and claims and discounts payable

    722(286)Accrued expenses

    54(617)Other long-term liabilities

    (75)(32)Net cash provided by operating activities

    $  3,073$  1,712Adjusted Earnings Per Share(Unaudited)For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, plus net loss attributable to noncontrolling interest divided by the weighted average diluted common shares outstanding.The following is a reconciliation of income before income tax provision to adjusted earnings per share:Three Months EndedSix Months EndedJune 30, June 30,In millions, except per share amounts

    2011201020112010Income before income tax provision

    $
    ,342$
    ,366$
    2,519$
    2,648Amortization

    114106220211Adjusted income before income tax provision

    1,4561,4722,7392,859Adjusted income tax provision(1)

    5715861,0761,138Adjusted income from continuing operations

    8858861,6631,721Net loss attributable to noncontrolling interest

    1



  • 21Adjusted income from continuing operations attributable to CVS Caremark

    $
    886$
    886$
    ,665$
    ,722Weighted average diluted common shares outstanding

    1,3641,3691,3681,381Adjusted earnings per share from continuing operations attributable to CVS Caremark

    $
    .65$
    .65$
    .22$
    .25(1) The adjusted income tax provision is computed using the effective income tax rate from the condensed consolidated statement of income.Free Cash Flow(Unaudited)The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).The following is a reconciliation of net cash provided by operating activities to free cash flow:Six Months EndedJune 30,In millions20112010Net cash provided by operating activities$
    3,073$
    ,712  Subtract:  Additions to property and equipment(710)(866)  Add:  Proceeds from sale-leaseback transactions11--Free cash flow $
    2,374$
    846Supplemental Information(Unaudited)The Company evaluates its Pharmacy Services and Retail Pharmacy segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:In millions

    Pharmacy Services Segment(1)Retail Pharmacy SegmentCorporate  SegmentIntersegment Eliminations(2)Consolidated

    TotalsThree Months EndedJune 30, 2011:

     Net revenues

    $
    4,589$
    4,826$
    --$
    (2,786)$
    26,629  Gross profit

    7294,408--(42)5,095  Operating profit (loss)

    4541,240(162)(42)1,490June 30, 2010:

     Net revenues

    $
    ,840$
    4,311$
    --$
    (2,144)$
    24,007  Gross profit

    8214,229--(30)5,020  Operating profit (loss)

    5911,096(156)(30)1,501Six Months EndedJune 30, 2011:

     Net revenues

    $
    28,603$
    29,413$
    --$
    (5,507)$
    52,509  Gross profit

    1,3688,555--(77)9,846  Operating profit (loss)

    8512,336(309)(77)2,801June 30, 2010:

     Net revenues

    $
    23,677$
    28,289$
    --$
    (4,199)$
    47,767  Gross profit

    1,6038,216--(53)9,766  Operating profit (loss)

    1,1302,125(291)(53)2,911(1) Net revenues of the Pharmacy Services segment include approximately $1.9 billion and $1.6 billion of retail co-payments for the three months ended June 30, 2011 and 2010, respectively, as well as $4.1 billion and $3.4 billion of retail co-payments for the six months ended June 30, 2011 and 2010, respectively.

    (2) Intersegment eliminations relate to two types of transactions: (i) Intersegment revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services segment customers, through the Company's intersegment activities (such as the Maintenance Choice™ program), elect to pick-up their maintenance prescriptions at Retail Pharmacy segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. As a result, both the Pharmacy Services and the Retail Pharmacy segments include the following results associated with this activity: net revenues of $626 million and $430 million for the three months ended June 30, 2011 and 2010, respectively, and $1.2 billion and $770 million for the six months ended June 30, 2011 and 2010, respectively; gross profit and operating profit of $42 million and $30 million for the three months ended June 30, 2011 and 2010, respectively, and $77 million and $53 million for the six months ended June 30, 2011 and 2010, respectively.Supplemental Information(Unaudited)Pharmacy Services SegmentThe following table summarizes the Pharmacy Services segment's performance for the respective periods:Three Months EndedSix Months EndedJune 30,June 30,In millions

    2011201020112010Net revenues

    $ 14,589$ 11,840$ 28,603$   23,677Gross profit

    7298211,3681,603Gross profit % of net revenues

    5.0%6.9%4.8%6.8%Operating expenses

    275230517473Operating expense % of net revenues

    1.9%1.9%1.8%2.0%Operating profit

    4545918511,130Operating profit % of net revenues

    3.1%5.0%3.0%4.8%Net revenues(1): Mail choice(2)

    $ 4,753$
    4,111$ 9,288$
    8,189Pharmacy network(3)

    9,7377,63019,11415,300Other

    9999201188Pharmacy claims processed(1):Total

    191.8144.3367.0291.7Mail choice(2)

    17.816.035.331.5Pharmacy network(3)

    174.0128.3331.7260.2Generic dispensing rate(1):Total

    74.1%71.0%73.9%70.7%Mail choice(2)

    64.6%61.0%64.2%59.9%Pharmacy network(3)

    75.0%72.2%74.9%71.9%Mail choice penetration rate

    22.6%25.9%23.3%25.4%(1) Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category.

    (2) Mail choice is defined as claims filled at a Pharmacy Services' mail facility, which include specialty mail claims, as well as 90-day claims filled at retail under the Maintenance Choice program.

    (3) Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity.EBITDA and EBITDA per Adjusted Claim(Unaudited)The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. We define EBITDA per adjusted claim as EBITDA divided by adjusted pharmacy claims. Adjusted pharmacy claims normalize the claims volume statistic for the difference in average days' supply for mail and retail claims. Adjusted pharmacy claims are calculated by multiplying 90-day claims (the majority of total mail claims) by 3 and adding the 30-day claims. EBITDA can be reconciled to operating profit, which we believe to be the most directly comparable GAAP financial measure.The following is a reconciliation of operating profit to EBITDA for the Pharmacy Services segment:Three Months EndedSix Months EndedJune 30,June 30,In millions, except per adjusted claim amounts

    2011201020112010Operating profit

    $
    454$
    591$
    851$
    ,130Depreciation and amortization

    10796205194EBITDA

    5616871,0561,324  Adjusted claims

    225.0173.2432.6348.7EBITDA per adjusted claim

    $   2.49$   3.96$
    2.44$
    3.79Supplemental Information(Unaudited)Retail Pharmacy SegmentThe following table summarizes the Retail Pharmacy segment's performance for the respective periods:Three Months EndedSix Months EndedJune 30,June 30,In millions

    2011201020112010Net revenues

    $14,826$14,311$29,413$28,289Gross profit

    4,4084,2298,5558,216Gross profit % of net revenues

    29.7%29.6%29.1%29.0%Operating expenses

    3,1683,1336,2196,091Operating expense % of net revenues

    21.4%21.9%21.1%21.5%Operating profit

    1,2401,0962,3362,125Operating profit % of net revenues

    8.4%7.7%7.9%7.5%Net revenue increase:Total

    3.6%3.7%4.0%3.6%Pharmacy

    3.9%4.2%4.5%4.4%Front store

    3.0%2.8%2.9%2.0%Same store sales increase (decrease): Total

    2.0%2.1%2.3%2.2%Pharmacy

    2.6%2.9%3.1%3.3%Front store

    0.8%0.4%0.6%(0.2)%Generic dispensing rate

    75.6%72.7%75.4%72.4%Pharmacy % of total revenues

    67.9%67.6%68.5%68.0%Third party % of pharmacy revenue

    97.7%97.2%97.6%97.2%Retail prescriptions filled

    162.4157.5328.0314.8Adjusted Earnings Per Share Guidance(Unaudited)The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.Year EndingIn millions, except per share amounts

    December 31, 2011Income before income tax provision

    $  5,671$  5,798Amortization

    460460Adjusted income before income tax provision

    6,1316,258Adjusted income tax provision

    2,4032,453Adjusted income from continuing operations

    3,7283,805Net loss attributable to noncontrolling interest

    44Adjusted income from continuing operations attributable to CVS Caremark

    $  3,732$  3,809Weighted average diluted common shares outstanding

    1,3551,355Adjusted earnings per share from continuing operations attributable to CVS Caremark

    $  2.75$  2.81Free Cash Flow Guidance(Unaudited)The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.Year EndingIn millions

    December 31, 2011 Net cash provided by operating activities

    $  5,500$  5,600Subtract:  Additions to property and equipment

    (2,100)(2,000)Add:  Proceeds from sale-leaseback transactions

    600550Free cash flow

    $  4,000$  4,150
    '/>"/>


  • SOURCE CVS Caremark Corporation
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. CVS Caremark Showcases Workplace and Marketplace Diversity at 2011 National Urban League Conference
    2. CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call
    3. Access Pharmaceuticals MuGard Added to CVS Caremarks Pharmacy Benefit Network
    4. CVS Caremark, Harvard and Brigham and Womens Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients
    5. CVS Caremark Corporation Announces Quarterly Dividend
    6. CVS Caremark to Present at the Jefferies 2011 Global Consumer Conference
    7. CVS Caremark and Area Colleagues Provide $40,000 of Support to Tornado Relief Efforts in Joplin, MO
    8. CVS Caremark Awarded Integrated 3-Year Blue Cross and Blue Shield Federal Employee Program (FEP) Contract
    9. CVS Caremark Developing New Ways to Help Patients Take Medications as Directed
    10. CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior
    11. CVS Caremark to Present at the Sanford C. Bernstein Strategic Decisions Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
    (Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
    (Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
    (Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
    (Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
    Breaking Medicine News(10 mins):